Sanofi launches global health brand, to offer 30 meds on non-profit basis

French drugmaker Sanofi will make 30 of its treatments, including insulin, available on a not-for-profit basis in 40 lower-income countries in the first step of its plan to increase access to its medicines worldwide.

The treatments will be provided under the new Impact brand, part of Sanofi's global health unit launched last year, which sits outside the commercial business.

The plan also includes the $25 million Impact fund, which will go towards supporting local start-up healthcare businesses and providing training on using the medicines, Sanofi said.


"There's a lot of noise at the moment from different companies jumping into this space... but investing in entrepreneurship, in the ecosystem, is a new thing," said Jon Fairest, who heads the global health unit.